Purpose Radio-nanomedicine, such as 125I-labelled TiO2 nanoparticles (125I-TiO2 NPs), presents a promising tumour treatment approach. By leveraging 125I as an electron donor to activate TiO2 NPs and promote γ-ray–induced H2O radiolysis, 125I-TiO2 generates reactive oxygen species (ROS) and induces DNA damage, thus enabling catalytic internal radiotherapy (CIR). Since DNA is a key target of radiation and ROS-induced damage, enhancing nuclear delivery is critical. However, lysosomal entrapment of 125I-TiO2 NPs greatly restricts the efficacy of CIR. To overcome this limitation, we conjugated 125I-TiO2 with transactivator of transcription/hemagglutinin-2 (125I-TiO2-TAT/HA2), hypothesising that TAT/HA2-mediated lysosomal escape and nuclear accumulation could improve the anti-tumour effects of 125I-TiO2. Methods TiO2 NPs and TiO2-TAT/HA2 were synthesised and labelled with 125I. Subcellular localisation was observed by confocal microscopy and biological transmission electron microscopy (bio-TEM). The effects of 125I-TiO2-TAT/HA2 on PANC-1 cells were assessed by the CCK-8 assay (cell viability), flow cytometry (apoptosis and ROS generation), proliferating cell nuclear antigen (PCNA) staining (proliferation), γ-H2AX immunofluorescence (DNA damage), and western blotting (DNA repair protein expression). In a subcutaneous pancreatic cancer mouse model, the intratumoural intra-tumoural retention of cyanine 5-labelled NPs (Cy5-NPs) was tracked via fluorescence imaging, whereas 125I-TiO2-TAT/HA2 was monitored by single-photon emission computed tomography (SPECT). Mice received intra-tumoural injections of DMEM, 125I, 125I-TiO2, or 125I-TiO2-TAT/HA2, and tumour volume and mouse weight and survival were recorded. Tumour glycometabolism was evaluated using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) before and after treatment. Haematoxylin and eosin (H&E), TdT-mediated dUTP nick end labelling (TUNEL), and immunohistochemical staining (Ki-67, DNA repair proteins) were performed. Results The labelling rates of 125I-TiO2 and 125I-TiO2-TAT/HA2 averaged 89.0% and 90.1%, respectively. Confocal microscopy and bio-TEM confirmed the nucleus-targeting ability of TiO2-TAT/HA2. In vitro, 125I-TiO2-TAT/HA2 significantly increased apoptosis and DNA damage and reduced DNA repair protein expression (RAD51and 53BP1) versus 125I-TiO2 (all p < 0.05). 125I-TiO2-TAT/HA2 additionally reduced PCNA expression and increased ROS production (both p > 0.05). In vivo, Cy5-NPs, 125I-TiO2, and 125I-TiO2-TAT/HA2 exhibited prolonged intra-tumoural retention. Tumours treated with 125I-TiO2-TAT/HA2 displayed a significantly smaller volume, enhanced necrosis and apoptosis (H&E, TUNEL), and downregulated DNA repair protein expression (all p < 0.05) and reduced Ki-67 expression (p > 0.05) compared with the effects of 125I-TiO2. Conclusion 125I-TiO2-TAT/HA2 exhibited markedly enhanced efficacy, likely through the precise nuclear delivery of ROS rather than increased ROS production. This strategy presents a promising method to improve tumour therapy, and it could be adapted for other macromolecular therapeutics.

Lysosome-escaping and nucleus-targeting nanomedicine for enhanced cancer catalytic internal radiotherapy

期刊论文
发表日期：

2025年7月1日

查看全文

Weiwei Su,
Han Wang,
Shuai Zhao,
Xiuru Ji,
Hongjing Jiang,
Kexian Li,
Changjing Zuo,
Jianming Zheng,
Dalong Ni,
Jiajia Hu

摘要

Purpose

Radio-nanomedicine, such as ¹²⁵I-labelled TiO₂ nanoparticles (¹²⁵I-TiO₂ NPs), presents a promising tumour treatment approach. By leveraging ¹²⁵I as an electron donor to activate TiO₂ NPs and promote γ-ray–induced H₂O radiolysis, ¹²⁵I-TiO₂ generates reactive oxygen species (ROS) and induces DNA damage, thus enabling catalytic internal radiotherapy (CIR). Since DNA is a key target of radiation and ROS-induced damage, enhancing nuclear delivery is critical. However, lysosomal entrapment of ¹²⁵I-TiO₂ NPs greatly restricts the efficacy of CIR. To overcome this limitation, we conjugated ¹²⁵I-TiO₂ with transactivator of transcription/hemagglutinin-2 (¹²⁵I-TiO₂-TAT/HA2), hypothesising that TAT/HA2-mediated lysosomal escape and nuclear accumulation could improve the anti-tumour effects of ¹²⁵I-TiO₂.

Methods

TiO₂ NPs and TiO₂-TAT/HA2 were synthesised and labelled with ¹²⁵I. Subcellular localisation was observed by confocal microscopy and biological transmission electron microscopy (bio-TEM). The effects of ¹²⁵I-TiO₂-TAT/HA2 on PANC-1 cells were assessed by the CCK-8 assay (cell viability), flow cytometry (apoptosis and ROS generation), proliferating cell nuclear antigen (PCNA) staining (proliferation), γ-H2AX immunofluorescence (DNA damage), and western blotting (DNA repair protein expression). In a subcutaneous pancreatic cancer mouse model, the intratumoural intra-tumoural retention of cyanine 5-labelled NPs (Cy5-NPs) was tracked via fluorescence imaging, whereas ¹²⁵I-TiO₂-TAT/HA2 was monitored by single-photon emission computed tomography (SPECT). Mice received intra-tumoural injections of DMEM, ¹²⁵I, ¹²⁵I-TiO₂, or ¹²⁵I-TiO₂-TAT/HA2, and tumour volume and mouse weight and survival were recorded. Tumour glycometabolism was evaluated using ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) before and after treatment. Haematoxylin and eosin (H&E), TdT-mediated dUTP nick end labelling (TUNEL), and immunohistochemical staining (Ki-67, DNA repair proteins) were performed.

Results

The labelling rates of ¹²⁵I-TiO₂ and ¹²⁵I-TiO₂-TAT/HA2 averaged 89.0% and 90.1%, respectively. Confocal microscopy and bio-TEM confirmed the nucleus-targeting ability of TiO₂-TAT/HA2. In vitro, ¹²⁵I-TiO₂-TAT/HA2 significantly increased apoptosis and DNA damage and reduced DNA repair protein expression (RAD51and 53BP1) versus ¹²⁵I-TiO₂ (all p < 0.05). ¹²⁵I-TiO₂-TAT/HA2 additionally reduced PCNA expression and increased ROS production (both p > 0.05). In vivo, Cy5-NPs, ¹²⁵I-TiO₂, and ¹²⁵I-TiO₂-TAT/HA2 exhibited prolonged intra-tumoural retention. Tumours treated with ¹²⁵I-TiO₂-TAT/HA2 displayed a significantly smaller volume, enhanced necrosis and apoptosis (H&E, TUNEL), and downregulated DNA repair protein expression (all p < 0.05) and reduced Ki-67 expression (p > 0.05) compared with the effects of ¹²⁵I-TiO₂.

Conclusion

¹²⁵I-TiO₂-TAT/HA2 exhibited markedly enhanced efficacy, likely through the precise nuclear delivery of ROS rather than increased ROS production. This strategy presents a promising method to improve tumour therapy, and it could be adapted for other macromolecular therapeutics.